Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL14002 vs Ranibizumab in wAMD
NCT07389577Phase 3Completed
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of JL14002 in exudative macular degeneration, sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoint: Best-Corrected Visual Acuity Change From Baseline at 12 weeks. Started Mar 2022; status: completed.
02
Drugs
JL14002
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT07389577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389577.